Plain-English translation of NCT06683846 on ClinicalTrials.gov ↗ ·
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a medication called Ivonescimab, which works by boosting your immune system to fight cancer cells. The study includes people with many different types of rare and advanced cancers — some common cancers are included too, but the focus is on cancers that don't have many other good treatment options. Researchers want to see how well and how safely this treatment works across these different cancer types.
Most cancer research focuses on common cancers, leaving people with rare cancers with very few options. This medication is designed to work differently than standard treatments by using your body's own immune system, and researchers hope it may help people whose cancers have stopped responding to other therapies.
You likely qualify if…
You likely don't qualify if…
You will receive the medication as an intravenous infusion (through an IV) once every 3 weeks. You will continue this treatment until your cancer gets worse, you experience unacceptable side effects, or you have completed 2 years of treatment — whichever comes first. You'll have regular clinic visits for imaging scans, blood tests, and check-ins to monitor how well the treatment is working and how you're feeling.
AI-generated summary from trial data · Jun 30, 2026 · Not medical advice
China